Viewing Study NCT04870151


Ignite Creation Date: 2025-12-24 @ 11:57 PM
Ignite Modification Date: 2025-12-30 @ 11:27 AM
Study NCT ID: NCT04870151
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-05-14
First Post: 2021-04-19
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Anterolateral Versus Direct Lateral Approach in Hemiarthroplasty for Hip Fracture
Sponsor: Sykehuset Innlandet HF
Organization:

Study Overview

Official Title: Anterolateral Versus Direct Lateral Approach in Hemiarthroplasty for Hip Fracture: A Randomised Study
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2025-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Patients with dislocated hip fractures are randomised to cemented hemiarthroplasty with an anterolateral approach or a direct lateral approach.
Detailed Description: Dislocated intracapsular hip fractures are usually treated with cemented hemiarthroplasty. In Norway, a direct lateral approach is most often used, as recommended in national guidelines. In total hip arthroplasty, however, minimally invasive approaches are also commonly used, and may improve the clinical results, as compared to posterior or direct lateral approaches.

The aims of the present study are to evaluate the effect of the minimally invasive anterolateral approach (Watson-Jones approach) compared to the direct lateral approach (Hardinge approach) to the hip joint in hemiarthroplasty after dislocated hip fractures.

Patients with dislocated hip fractures who are fit for cemented hemiarthroplasty are randomised to surgery with an anterolateral approach or a direct lateral approach.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: